News | October 11, 2012

Edwards Lifesciences Acquires Hemodynamic Monitoring Company BMEYE

Critical care portfolio expands to include noninvasive platform

October 11, 2012 — Edwards Lifesciences Corp. announced it has completed the acquisition of BMEYE B.V., a privately held Dutch company that specializes in the development of noninvasive technology for advanced hemodynamic monitoring. BMEYE's technology provides continuous, real-time information to clinicians and can be used in the surgical, intensive care, emergency room and cardiology settings.

"BMEYE's unique noninvasive technology platform complements our existing portfolio and will provide clinicians with critical, comprehensive hemodynamic monitoring information for a broader range of patients. Numerous studies have concluded that therapy guided by hemodynamic monitoring improves patient outcomes and reduces complications and lengths of hospital stays," said Carlyn Solomon, Edwards' corporate vice president, critical care and vascular. "This acquisition supports our ongoing commitment to build and strengthen our offerings for clinicians and patients, and reinforces our leadership in hemodynamic monitoring."

BMEYE's monitoring products work with a noninvasive finger cuff to measure continuous, real-time information on cardiac output, blood pressure, fluid responsiveness and other important hemodynamic parameters. Currently, BMEYE's products are approved for sale in the United States, throughout Europe and in several other countries.

BMEYE CEO Rob de Ree said, "BMEYE has a solid history of developing innovative hemodynamic monitoring solutions. We look forward to joining the Edwards team to extend the reach of our existing products, and to continue to develop novel technologies to help clinicians and improve patient care worldwide."

While BMEYE's products have primarily been used by clinicians outside of the hospital, over the next 18 months Edwards plans to further develop the technology and integrate it into the Edwards EV1000 clinical platform for use in the acute care setting in hospitals.

For more information: www.edwards.com

Related Content

The Fysicon QMAPP hemodynamic monitoring system is the newest system to gain FDA clearance. It is about the size of a ream of paper.

The Fysicon QMAPP hemodynamic monitoring system is the newest system to gain FDA clearance. It is about the size of a ream of paper.

Feature | Hemodynamic Monitoring Systems | September 05, 2018 | Dave Fornell, Editor
Beyond measuring blood flow, pressure, oxygen levels and other vital signs in the cardiac catheterization lab, curren
Fysicon Receives FDA Approval for QMAPP Hemodynamic Monitoring System
Technology | Hemodynamic Monitoring Systems | September 18, 2017
Fysicon announced that it has been granted 510(k) clearance by the U.S. Food and Drug Administration (FDA) for its...
Merge Hemo cath lab hemodynamics monitoring system.

Hemodynamic data shown on screens from the Merge Hemo recording system. It is among the newer generation hemodynamic systems for cath labs that are more user friendly and have technologies to speed workflow.

Feature | Hemodynamic Monitoring Systems | August 03, 2017 | Dave Fornell
The current generation of...
Siemens, Sensis Vibe hemodynamic system, ACC 2016
Technology | Hemodynamic Monitoring Systems | April 01, 2016
Siemens will unveil a revamped version of its established Sensis hemodynamic system at the 65 th Annual Scientific...
Feature | Hemodynamic Monitoring Systems | January 12, 2016 | Dave Fornell
Beyond measuring blood flow, pressure, oxygen levels and other vital signs in the cardiac catheterization lab, curren
Overlay Init